Skip to main content
Top
Published in: Rheumatology International 9/2012

01-09-2012 | Original Article

Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study

Authors: Simeon Grazio, Zvonko Kusić, Selma Cvijetić, Frane Grubišić, Antonija Balenović, Tomislav Nemčić, Valentina Matijević-Mikelić, Marija Punda, Joachim Sieper

Published in: Rheumatology International | Issue 9/2012

Login to get access

Abstract

In ankylosing spondylitis, inflammatory activity probably plays a key role in the pathophysiology of bone loss. The aim of the study was to investigate the relationship of bone mineral density (BMD) at the lumbar spine and hip region with some measures of disease activity and functional ability in patients with ankylosing spondylitis. In 80 patients with established ankylosing spondylitis, disease activity and functional ability were determined by C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI). Spinal pain and patient global health were assessed using horizontal visual analog scale. BMD was measured by dual-energy X-ray absorptiometry. There was a significant negative correlation of bone density T scores with acute-phase reactants (i.e., patients with lower T scores had higher level of CRP and ESR). That relationship was reflected more reliably at proximal femur sites than at the lumbar spine. There were also significant differences in ESR, BASDAI, BASFI, spinal pain and global health between three groups of patients according to WHO classification of osteoporosis (normal, osteopenic and osteoporotic). Significantly, more patients with osteopenia at the lumbar spine had lower BASDAI index than those with normal BMD (P = 0.030). Our results indicate an association of low BMD with high disease activity in patients with AS. Femoral BMD seems to be more associated with disease activity and functional ability than lumbar spine BMD.
Literature
1.
go back to reference Thomas GP, Brown MA (2010) Genetics and genomics of ankylosing spondylitis. Immunol Rev 233:162–180PubMedCrossRef Thomas GP, Brown MA (2010) Genetics and genomics of ankylosing spondylitis. Immunol Rev 233:162–180PubMedCrossRef
2.
go back to reference Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Falon WM, Melton J (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882PubMed Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Falon WM, Melton J (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882PubMed
3.
go back to reference Hunter T, Dubo HIC (1983) Spinal fractures complicating ankylosing spondylitis: a long-term follow-up study. Arthritis Rheum 26:751–759PubMedCrossRef Hunter T, Dubo HIC (1983) Spinal fractures complicating ankylosing spondylitis: a long-term follow-up study. Arthritis Rheum 26:751–759PubMedCrossRef
4.
go back to reference Ralston SH, Urquhart GDK, Brzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 300:563–565PubMedCrossRef Ralston SH, Urquhart GDK, Brzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 300:563–565PubMedCrossRef
5.
go back to reference Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 26:30–34PubMedCrossRef Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 26:30–34PubMedCrossRef
6.
go back to reference World Medical Organization (1996) Declaration of Helsinki. Brit Med J 313(7070):1448–1449 World Medical Organization (1996) Declaration of Helsinki. Brit Med J 313(7070):1448–1449
7.
go back to reference Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed
8.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291PubMed
9.
go back to reference Grazio S, Grubišić F, Nemčić T, Matijević V, Skala H (2009) The reliability and validity of a Croatian version of the bath ankylosing spondylitis functional index and bath ankylosing spondylitis disease activity index in patients with ankylosing spondylitis. Reumatizam 56:63–76 (article in Croatian)PubMed Grazio S, Grubišić F, Nemčić T, Matijević V, Skala H (2009) The reliability and validity of a Croatian version of the bath ankylosing spondylitis functional index and bath ankylosing spondylitis disease activity index in patients with ankylosing spondylitis. Reumatizam 56:63–76 (article in Croatian)PubMed
10.
go back to reference Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to world health organization criteria for osteoporosis and osteopenia. Bone 27:585–590PubMedCrossRef Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to world health organization criteria for osteoporosis and osteopenia. Bone 27:585–590PubMedCrossRef
11.
go back to reference Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX™, the assessment of fracture probability in men, women from the UK. Osteoporos Int 19:385–397PubMedCrossRef Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX™, the assessment of fracture probability in men, women from the UK. Osteoporos Int 19:385–397PubMedCrossRef
12.
go back to reference WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129 WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129
13.
go back to reference Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef
14.
go back to reference McDonald BR, Gowen M (1992) Cytokines and bone. Br J Rheumatol 31:149–155CrossRef McDonald BR, Gowen M (1992) Cytokines and bone. Br J Rheumatol 31:149–155CrossRef
15.
go back to reference Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor-alpha treatment. J Rheumatol 35:855–861PubMed Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor-alpha treatment. J Rheumatol 35:855–861PubMed
16.
go back to reference Barnabe C, Hanley DA (2009) Effect of tumour necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 39:116–122PubMedCrossRef Barnabe C, Hanley DA (2009) Effect of tumour necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 39:116–122PubMedCrossRef
17.
go back to reference Visvanathan S, van der Heijde D, Deodhar A et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175–182PubMedCrossRef Visvanathan S, van der Heijde D, Deodhar A et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175–182PubMedCrossRef
18.
go back to reference Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347–349PubMedCrossRef Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347–349PubMedCrossRef
19.
go back to reference Laan R, Buijs W, Draad M et al (1991) Bone mineral density in rheumatoid arthritis: influence of disease activity and functional capacity. Arthritis Rheum 34:S180CrossRef Laan R, Buijs W, Draad M et al (1991) Bone mineral density in rheumatoid arthritis: influence of disease activity and functional capacity. Arthritis Rheum 34:S180CrossRef
20.
go back to reference Yildirim K, Karatay S, Cetinkaya R et al (2009) Bone mineral density in patients with familial Mediterranean fever. Rheumatol Int 30:305–308PubMedCrossRef Yildirim K, Karatay S, Cetinkaya R et al (2009) Bone mineral density in patients with familial Mediterranean fever. Rheumatol Int 30:305–308PubMedCrossRef
21.
go back to reference Sieper J (2009) Can structural damage be prevented in ankylosing spondylitis? Curr Opin Rheumatol 21:335–339PubMedCrossRef Sieper J (2009) Can structural damage be prevented in ankylosing spondylitis? Curr Opin Rheumatol 21:335–339PubMedCrossRef
22.
go back to reference Başkan BM, Doğan YP, Sivas F, Bodur H, Özoran K (2010) The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 30:375–381CrossRef Başkan BM, Doğan YP, Sivas F, Bodur H, Özoran K (2010) The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 30:375–381CrossRef
23.
go back to reference Ghozlani I, Ghazi M, Nouijai A et al (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 44:772–776PubMedCrossRef Ghozlani I, Ghazi M, Nouijai A et al (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 44:772–776PubMedCrossRef
24.
go back to reference Gratacos J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef Gratacos J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef
25.
go back to reference Incel NA, Gokoglu F, Nacir B, Incel N (2006) Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 25:667–670PubMedCrossRef Incel NA, Gokoglu F, Nacir B, Incel N (2006) Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 25:667–670PubMedCrossRef
26.
go back to reference Lange U, Teichmann J, Strunk J, Müller-Ladner U, Schmidt KL (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16:1999–2004PubMedCrossRef Lange U, Teichmann J, Strunk J, Müller-Ladner U, Schmidt KL (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16:1999–2004PubMedCrossRef
27.
go back to reference Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 40:882–888PubMedCrossRef Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 40:882–888PubMedCrossRef
28.
go back to reference Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F (2007) Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Jt Bone Spine 74:249–253CrossRef Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F (2007) Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Jt Bone Spine 74:249–253CrossRef
29.
go back to reference Przepiera-Bedzak H (2007) The value of researches, which assess bone mineral density and bone metabolism in patients with ankylosing spondylitis, in detecting osteoporosis. Ann Academ Med Stetinen 53:39–47 (article in polish) Przepiera-Bedzak H (2007) The value of researches, which assess bone mineral density and bone metabolism in patients with ankylosing spondylitis, in detecting osteoporosis. Ann Academ Med Stetinen 53:39–47 (article in polish)
30.
go back to reference Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32:1290–1298PubMed Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32:1290–1298PubMed
31.
go back to reference Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18(Suppl 21):S16–S20 Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18(Suppl 21):S16–S20
32.
go back to reference Borman P (2004) Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 24:59–60CrossRef Borman P (2004) Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 24:59–60CrossRef
33.
go back to reference El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Jt Bone Spine 71:291–295CrossRef El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Jt Bone Spine 71:291–295CrossRef
34.
go back to reference Capaci K, Hepguler S, Argin M, Tas I (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44(3):379–384PubMed Capaci K, Hepguler S, Argin M, Tas I (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44(3):379–384PubMed
35.
go back to reference Mitra D, Elvins DM, Speden DJ, Collins AJ (2000) The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 39:85–89PubMedCrossRef Mitra D, Elvins DM, Speden DJ, Collins AJ (2000) The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 39:85–89PubMedCrossRef
36.
go back to reference Grubišić F, Grazio S, Balenović A, Nemčić T, Kusić Z (2009) Osteoporosis, spinal mobility and chest expansion index in patients with ankylosing spondylitis. Coll Antrop (accepted for publication) Grubišić F, Grazio S, Balenović A, Nemčić T, Kusić Z (2009) Osteoporosis, spinal mobility and chest expansion index in patients with ankylosing spondylitis. Coll Antrop (accepted for publication)
37.
go back to reference Sarikaya S, Basaran A, Tekin Y, Ozdolap S, Ortancil O (2007) Is osteoporosis generalized or localized to central skeleton in ankylosing spondylitis? J Clin Rheumatol 13:20–24PubMedCrossRef Sarikaya S, Basaran A, Tekin Y, Ozdolap S, Ortancil O (2007) Is osteoporosis generalized or localized to central skeleton in ankylosing spondylitis? J Clin Rheumatol 13:20–24PubMedCrossRef
38.
go back to reference Lange U, Jung O, Teichmann J, Neeck G (2001) Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 12:1031–1035PubMedCrossRef Lange U, Jung O, Teichmann J, Neeck G (2001) Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 12:1031–1035PubMedCrossRef
Metadata
Title
Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study
Authors
Simeon Grazio
Zvonko Kusić
Selma Cvijetić
Frane Grubišić
Antonija Balenović
Tomislav Nemčić
Valentina Matijević-Mikelić
Marija Punda
Joachim Sieper
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2066-9

Other articles of this Issue 9/2012

Rheumatology International 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.